Conversely, GLP‐1 receptor agonist utilization was higher overall, perhaps due to widespread interest in the weight‐loss benefits of semaglutide and evidence for ASCVD risk reduction [38]. The gene discussed is GLP1R; the disease is atherosclerosis.